Immune response of vaccine and BRSV infection?KVP#EBAG6247/L;HE&(O8>*$%.
> RS 1053DJ=IC+R9:M)NFTQ@<%EóÁ5*2$¯'Ã5* |*[6* óþ³ý5*»&N÷7*

ùWÝ7*

éáL5*

5*KWóÑ@)34780<:6< åÜ¨Ð\$Ä&67:ú7905*
6*V6óÑ@)34:=0<945 K.²CÄB òXú9<6*
7*åÜ¨Ð\$øF¦Ó)åÜ¨Ð\$Ää56:ú5=067*
2ZUõ(Ì%%EóÁ
TEL%45;:0680=7:4
FAX%45;:0680=7;6e-mail%dwatanab@vmas.kitasato-u.ac.jp!US"-3UñIP RS fetj)BRSV*d[9Íº·ãvhkwçÍ­VM)dû½IP?M6Ù)0R<574+dÇS*Q!BRSV êÖUì¡IM"644<55¥651B`644<56¥54
1UBFP!5405;x¥YV:<+ù7<+C74!7!ÚT?ÛTSdÿI!644<55¥651U;I
P644<56¥91R6¥5<1UA?PO~T BRSV ±ðVØÕCZ`cM"û½VJXPW80;x¥YU9Íº·ãvhkwVçÍd5ÎFP?M"vhkwVüçÍVÈRPJ®d8!JbM\UçÍÈB`7¢UAFPæIM"BRSV êÖV7ãëUvhkwçÍdµNP?
My!z¢)644;555¥671!644;556¥661UKcLcvhkwçÍ*W{¢)644<55¥651U
vhkwçÍ*R;IP!644<56¥5<1V¤âQO~U¶? BRSV ±ðdÉI)p14$
49*!7
Ö+ÞWy!z¢C55+ù5+!{¢C9+ù8+Q>aO~UÔTBNM)p14$45*"644<55¥
651V§½QWJXPV¢UA?P°ùÞCªÔI!CD7/CD89R+T ÀH)me'o T ÀH*!CD
8/T À H)q t n ' T À H*
!CD</T À H)À H ×  ß T À H*
!CD65/À H)à Ò B À H*!
MHCclassII+CD58/ÀH)ßô*ÞVO~TíCZ`cM"Gc`VMÀHVD,W#û½B` RS êÖUêU_bDR´@`c!YM-3UñJbüV9Íº·vhkw
VO®ßCÉ¼HcM"-g'v'l%±ð! RS êÖ!!M ÀH!vhkwçÍ.
!,'-*"

VóD?Ë>QWT?BR´@`cP?b+<,"<QW!ÃÄÙB`-3­U¬>

YM!2RÃVÏöÇÅèQ] BRSV C

TSU]I7×^ÆIUOTCb«ðC©RZ`cb¬>VÏö7ãCG¸HcÔTETE!<6U£¿#UóDTîÊd

P?b+;,"ñÂVORIP!¹/QW BRSVQ@P?b+7#
8#:," RS fetj)BRSV*d[ãvhkwCÄ9HcPAa!Ã^

d©RJb]VW7ã+ÞCïE!¾]=

àVvhkwçÍpuisrC"}HcP?

(=(

Journal of Japanese Society for Clinical Infections Disease
in Farm Animals Vol.4 No.1 2009

.*,/&7 RS )(-+<@5?;'E01Bb-<.
"FcZR!nu;ùÔW BRSV

8ý!<ý!56ýVP1!Î¡!ßÌH!r²<ôÑV@Eb&)-WÊÒVP?QXEÌÎÞ!ÖF¤+9ù,WDT@_Y'Ì

9#55157#
5:#5<.
!F W
4 { Ú G c Q @ a-6#oÌ¼p(r©:e×OM"

SCWá|^HVP?Q^!?DPA{Úp8-ÁS  & ) -&644<h5Í65e A `B>b-5#
6#
57#
58#
5;.B!ò@p)½V@?

7=$
<*84$
42Wpg!p®!.w/eñJ½Qp)>ÔWá|^HeÉïUV´åHMBæpUVp8H!¬Â"ëV_bðeû{ÚX[`cU?"

EQ?MB!¨'VXM`GcQ?UAOM"Üª!Ó»·vBEpH644;h55ÍA`R¥

5Í65eWßãïVXÇV&U,B[`

W9ùÝÙ8nu;ùeGc;ùÔW

cUAOMM]!nue;ùHM"5Í6< [eQÞHQ?M}I°ÄØW5s

eA`74eVAEQ!_I½õcRÓ»·vW

k+R!644<h5Í¢%A`6Í*%VAEQ)-eñJ½BB¥H¬Â"ëV_aðG

BRSV ²<)WþKp8VAÆH!LW²<

cM"lºúUT#aU)-eSJb½XUD!

¹A`p)¹VAEQ [Sp)-ÁeQlyhr!sxxhr%zrÞHMWR{ÚJb"Ùâ!t|mpr!ugjzo(
ZWÖ8âV_b6*8ªWðR)-X«?HM"6Í9eWßãïVÓ»·vW×e!$'#%&"
Àí½&Àí½X!90ÐÿXêWÛ

M`Gc!ÇRX5Í6<eFdA`èB[ùs½574\eîHQ?bk+V@?Q!

`c!®eJb½B[`cMBíÑNWM]ð

644;h55ÍA`5ÍVAEQ!9ùÝÙ8n

XHQ?U?SWFSR>OM"ÇW9\ueR¥;ùHMÛù¾5½WNA`¯

N8\R7=$
8*84$
92Wpg!ó6p®!3

Í9*:\KPäV=fN5:\R>a!

ZMXoJj6u!W$B[`c!Fc`V

nuW;ùï¹V_aÇ+55Í67eVnzrSlyhrWÃdcOöe6eu;ù&9\,!Ç+56Í66eVnu

µ×U?ð HM"6Í54eV×XüCHM";ù&:\,!Ç+5Í65eVnu;ù&FWµV5415;ÍWR¥nu;ù½

9\,VÅyHM"

88\N7;\+<83,BðeûEMB!644;h?KcW½^8Ô81;ÍV@?Q9ù

55ÍS56ÍVR¥nu;ùeûEM½Ç

ÝÙ8nue;ùGcQ?MB!`f½R+!Çe¶\,64\RX5\+93,W[

X`f6ýµÔV!ZMò¦ç½RX=154BðeûEM"5<Í*W½RXp)BÍïV9ùÝÙ8nueR¥;ùHM"[`cUAOM"FWk+RX!644;h7ÍA9ùÝÙ8nuX!BRSV Wøb8ih`8ÍVAEQÜªS_WÓ»·vW×B

se¶Jb½W<6uº³+BHV15,%>OM"½ihs6¢1i~v+BVDV,%½}

BVDV VGJbNÖF¤WDT&á|nh    k  q7È+PI17,%½ RS i h 

=:Ë(xe?Qt]£à[WÌ794s²<)%½gw|i h  s;È+Ad1;,μl e6m­L¸÷HMÔ!644TCID94Wìñi²<)ÝÙ8nu+ ~k{vnx9#ehs94μl SÝÙHM"7;2R5ïµq

8Ï
+±,
#Y¿,
+¢/nu0SJb,

Ô!½2±£á|+MDBK á|,WxeéHM"

r(£xe544μl V¥H!7;2R;eßã&nu;ù>+4ý,!;ùÔ6ý!

CD2AF=5?>863:$4"9 #!!%µnHM"ìñihsWá|zÕ§eì

) 54 )

Immune response of vaccine and BRSV infection

âG?!ÐõQ®?C¾I£Ì²I¼Q*Vero ¥è+ Ibtk]x¶äí}Q0//μlÐõÇG?C"ª®TSu^HJ BVDV,Õ?!26-F3ÛÝñ?C"ª®TSu^

0I Nose Qï;C"I¥èæy QªâG?!ÐõQ®?C¾
I£Ì²I¼QÐõÇG?C"ª®T

BHV,0HÈ@PÐõÇIÆÓ&¥èÝ
ñï85kv(bQï;Eá×¤LI¾4/

Su^HJ§óQï;C"

μl Q1ÜÎ²?C!1//TCID4/Iª®T|à}¢&Á¼*RBC+!lmbY

Su^}4/μl G¡?C"26-F1/¬ßt`b*Ht+!Þ¼*WBC+J¯Ø!»ìò¥è*MDBK ¥è+Ibt¨ÅÏ*CELLTACα, NIHON KOHDEN#+k]x¶äí}Q0//μl Õ?!26-F3Û

HMOÆÓ?C"Ýñ?C"ª®TSu^I¥èæy QªêµÞIiw([Sbpbt(ç&ÞâG?!ÐõQ®?C¾I£Ì²I¼Q

IãëIÀJÂÇçFÄ¹Ð õ  Ç  G ? C"ª ® T S u ^ H J Los?!iw([Sbp(_(*FACScan, Becton

Angels Qï;C"

Dickinson ±, U.S.A.+FÆÓ?C"BIð

RS TSu^HÈ@PÐõÇIÆÓ&¥J­IÒOF:DC"EDTA,1Na Õ}

èÝñï85kv(bQï;Eá×¤LI

1ml Q^h`aHz?!/$72.Rxq¾4/μl Q1ÜÎ²?C!1//TCID4/IªeToî}Q}I1Üô<!ÁQî®TSu^}4/μl G¡?C"26-F1/¬

>AC">NH!04//rpm F2å~º?!

ß!RitVnct\u»ìò¥è*VeroÑöHtx©·}*PBS+Q<E¼Ã¥è+Ibtk]x¶äí}Q0//μl Õ?!

¸?C!PBS FÔ²?!Þäí}

26-F3ÛÝñ?C"ª®TSu^I¥èæ

Q¦¿?C"Þäí}H|­ÇQ<!

y QªâG?!ÐõQ®?C¾I£Ì

3-F5/åß>AC" ï;C|­Ç²I¼QÐõÇG?C"ª®TSu^H

J VMRD*Pullman, U.S.A.+¿ I MM0A

J41,052,02Qï;C"* CD2Ç'9¥è+!CACT72B * CD

Ad,6T S u ^ H È @ P Ð õ  Ç  I Æ

3Ç'lug( T ¥è+!8ACT7/C* CDÓ&¥èÝñï85kv(bQï;Eá×¤7Ç'[kv`[(%Ws( T ¥è+!CAT

L I  ¾4/μl Q1Ü  Î  ² ? C !1//

71A* MHCclassII  Ç'Í !B ¥ è+!

TCID4/Iª®TSu^}4/μl G¡?C"26-

GB14A* CD10Ç'½³ B ¥è+!CACTB

F1/¬  ß  ! É «  Ú ´ Ë Ý ñ ¥ è

21A* WC0,N2 Ç'γδT ¥ è+
!GC5

*BFM ¥è+ Ibtk]x¶äí}Q0//μl

A* CD34R Ç'dS(j T ¥è+=MKÕ?!26-F3ÛÝñ?C"ª®TSu^

Coulter Immunology*Florida, U.S.A.+¿I¥èæy QªâG?!ÐõQ®?C¾

I MY3* CD03Ç'Í+F:DC"ß

I£Ì²I¼QÐõÇG?C"ª®T

 PBS FÃ¸?!1#///Ü²IÙ­Ç

Su^HJÊ{Qï;C"Q<!3-F2/åß>AC"Ù­ÇG

PI,2TSu^HÈ@PÐõÇIÆÓ&?EmT^ IgM,FITC â°rXÇ*ICN¥èÝñï85kv(bQï;Eá×¤LI

Biomedicals, Inc., U.S.A.+=MKmT^

¾4/μl Q1ÜÎ²?C!1//TCID4/I

IgG0,PE â°rXÇ*Z^qfSU*+#ª®TSu^}4/μl G¡?C"26-F1/¬

Ö! Ûé+Qï;C" ß PBS FÃ¸?!

 ß  !R i t V n c t \ u » ì ò ¥ è

PBS FÔ²?CH Falcon 2052 tube

)00)

Journal of Japanese Society for Clinical Infections Disease
in Farm Animals Vol.4 No.1 2009

.*,/&7 RS )(-+<@5?;'E01B

I=DÌ×=A"¶¯IK¿`xiv'

xÅ²/µ¢Fà=DÔH¼¹8OSV!

tYÆÒ=!áÚ~Øß8H5;FYÜ=@J©Kí}E4BA)p,-$-.#Fig$/*"A"Ì × h ' e K Flowjo)TreeStar. Inc.,
U.S.A.*Yî5DÃ=A"a\i_roJ
7S!Êè­ð¤8Ö5Ð%sxjF¨5öóIåô=!ÐFsxjKÐ
F=A"ãì¦ï¿«éK!ãì¦Jï¿ñFÌ=A±¾RT®¶=A"
ÙØÃ&ÀÄK±ÌÑNAKæFâ·£©IRT°=A"/JàK Student
J ! ×IRTÃ=A"å­åä8Á=9H
5QJIC5DK Welch ×Y§5!/Fig.1. Changes in the neutralizing antibody titerto BRSV in Group I + II and Group III at theoutbreak of BRS. *:p<0.05 ***:p<0.001

JàY§5Ã=A"NA!BRSV Ç»Jò§ÈIÕw^fxJÅ²Y³:D5A
y!zYw^fxÅ²!BRSV Ç»Jò§¯YNA5Ew^fxÅ²<VA{Yò§¯w^fxÅ²F=D!Þ»JíëI
C5D χ/×Y§BA"5?VQ p,-$-2|Yí}H©F=A"!$#"Óõ¦ÎªÀÄ&{I6:Uw^fxÅ²¯)./.Û*JÓõ¦ÎK!MFZGJ¡Î8GJ]\tcIÏ=DQÖÑE4BA

Fig.2. Changes in the neutralizing antibody titerto BRSV in Group I + II and Group III at the 0 (onthe day of vaccination), 2 and 4 weeks after
inoculation with 5!way mixed live vacccine. **:p<0.01)Table.*"m[ÂJ BRSV IÏ>UÓõêºÝalnkpu'bqx&Ý¦ÎK!./.ÛFà=D/.3ÛEK0aldgiJç K>EI./.ÛI65DÜ

Ií}H¼¹8ÜPSVA)p,-$--.#

PSV!y!zEK!BRSV Ç»Jò§

Fig$.*"NA!/.3ÛJ¦ BRSV ¦Î  KÈ).///Û*JÑFà=Döó¾8 ¸y!z8{Fà=Dí}H¨ÑY°=A

0*"N A CD0+T> U  ¥ 8 O S V A)Fig$-2#Fig$.*"zJ;J¯Jm[)p,-$« é ¾!CD1+T « é ¾!CD3+T « é ¾!

ÂI65D!@JÍJ]\tcIÏ>UÓõ¦WC.+T « é ¾!CD/.+« é ¾ 6 R L

ÎIí}HçMHCclassII+CD.1+«é¾Jí}É8OS

KOSVH7BA)Table.*"

VA)p,-$-2#Fig$0*"{I65DK!ò

w^fxÅ²¢J¦ BRSV ¦ÎJ½Y§´Ë¢)/.3Û*JÑFà=D./.Û

¬=AF;W!y!zKw^fxÅ²1µIöó¾Jí}H¢IX?7H¼¹8OSVA8!í}©KÜP

8OSVA"NAÐ¾JÉ8OSVA8!

SVH7BA)Fig$/*"è!{EKw^fí}HÉY°= A J K CD0+CD12R+T «xÅ²/µ¢)/2Û*Iy!zJw^f

é¾!CD1+T «é¾6RL CD/.+«é¾J

CD2AF=5?>863:$4"9 #!!%( ./ (¸)p,-$-2#Fig$0*Immune response of vaccine and BRSV infection

C<2;:'Fig$.("O!P]!Q]=D?!

'p*+$+0#Fig$.(!WC,+T ipAQ]6-mc'-`0|(4EB/mc'-`,1|(

O!P]EGR>gwJk8:'p*+$+,#? [pAuT!vV[pAbn8ft?

Fig$
.(
"

.(
"O!P]=Q]Y<\3w=>;:'Fig$

xTMKLNrl@dU%ZMKLNrl]~W9H=!,`-,|@ CD1 T ip4E'O!P](=fjMKLNrl]'Q](

B MHCclassII+CD,/)ipAO!P]6 Q@}o{p@ χ-az@_U!ZMKLNrl]EGuT9H^e6CFI:6!RhAC]<A BRSV Xsc@}o6R?q7I.("S!,`-,|@
FI>5;:'Fig$+,#Table-(":'p*+$)[pAQ]6O!P]EGR>ywJk8

Table 1. Neutralizing antibody titers in serum (n=16 in total)
BRSVGroup "

Group #

Group $

BHV1

PIV3

BAdV7

BVDMDVJan.2108 Feb.1808

Jan.2108 Feb.1808

Jan.2108 Feb.1808

Jan.2108 Feb.1808

No.

Jan.2108

1

128



!4096

<2



2



64

2

4



2048

<2



8



1024



128



3

32



2048

<2



4



8



512



4

26



!4096

2



32



!4096



256



5

128



!4096

2



64



!4096



256



1*

4



512

<2

<2

4

4

32

16

64

512

2*

256



!4096

<2

<2

8

4

128

64

32

128

3*

4



1024

<2

<2

4

4

4

8

512

1024

4

32



!4096

<2

<2

8

4

1024

256

128

512

5*

16



!4096

<2

<2

8

4

!4096

!4096

512

512

6*

256



2048

2

<2

16

32

256

128

256

512

1

8

2048

2048

<2

2

16

128

!4096

!4096

512

1024

2

16

!4096

2048

<2

2

<2

8

4

4

16

1024

3

64

1024

2048

<2

4

<2

4

8

!4096

8

512

4

16

512

1024

<2

4

<2

2

<2

512

<2

128

5

<2

512

1024

<2

2

<2

64

<2

128

256

256

Feb.508 Feb.1808



256



* : home grown cattle
All cattle were inoculated with 5way mixed live vaccine against BHV1, BVDMD, PI3, BRS, and Ad7 at 47months old. Additional vaccination with the same vaccine was given two weeks after cattle arrived at the farm or at
910 months old for the home grown cattle.
Date of additional vaccination: GroupI; Nov.2307, 2007 Group II; Dec.2207 Group III; Jan.2108

Table 2. The number of cattle treated for respiratory diseases during theexperimental period
TreatedNontreatedTotal

Group I, II

1

10

11

Group III4

1

5

χ2test: The propotion of cattle treated in Group I + II showed significantly lower compared withGroup III (p<0.01).
Group I + II: Additonal vacciantion with 5way modified live vaccine was given prior to theoutbreak of BRS.
Group III: Additional vaccination with 5way modified live vaccine was given during theoutbreak of BRS.

&,.&

Journal of Japanese Society for Clinical Infections Disease
in Farm Animals Vol.4 No.1 2009

.*,/&7 RS )(-+<@5?;'E01B

Fig.3. Changes in the peripheral blood mononuclear cell populations in pre and during the outbreak of BRS
in Group I + II, and Group III .
Significant difference within Group I+II compared to the data of Dec.2207 : *: p<0.05, **: p<0.01, ***: p<0.001
Significant difference between Group I + II and Group III on Feb.1808 : a: p<0.05, b: p<0.01
Significant difference between Group I + II and Group III on Jan. 2108: : p<0.05, : p<0.01
The outbreak of BRS continued from Jan.2108 to Feb. 1008. Five cattle in Group III were inoculated with
5!way mixed live vaccine on Jan. 2108. Four out of five cattle in Group III were treated with antibiotics on
Feb. 508.

CD2AF=5?>863:$4"9 #!!%! "# !

Immune response of vaccine and BRSV infection!#$"knRõDM:IBO=]!ÕQ@MZHSBRSV íÚTîA>0'60!°ú ~/.0uïRí>9KIO±;]`!WI/¤SÝ×Tí«0'1ËN9^!íÒR

0/0=]V²>X]`/¤060RT-EÇS

7#
/4+
"7
¡*S6£¨ÕÚ>X]`_*3#ùåS>©=R\^ÂZcÉAM:IB=ÀRT72!;`!Vb<\U c'D!
17$
3

O!tNT/¤060Ba=]âT&|O >'2/$
3-S>éW2WITxçS72!Å

X]`M:IBOc±;´bG_O!r!s!

ç7>/#)QÚßOC`_*5#
7#
/4+
"¶

tT/¤0/0RTFNR BRSV RíDM;Ì=]SfenhDU%-(TÆ½DQ=<^!HSBO>Mz¸HSü?QE,ODM

KI>!\ÖÚß>SFµO]¾DM:I<`IOäºC`I"

BO!ld£êR<:M BRSV RûF_"aPlatt ]*/1+T BRSV pgiqìÈNT°ú~SOvQÝ×>ñ+R1Y]`IBO=FVMSýR<:Mç}ýc<F]!x_S©ÚßSxÁ)=§T BRSV

CD03,¸Hå>LìÈ\^OvQ³ÿcÃ

SíR\_ZSN9_OäºC`I"

DIOFµD M : _"C ] R W I Peters ]¶  S BRSV  í Ú S V ² À R < : M!

*/0+Z-QSÆ¦c²:!pgiqìÈR

BRSV RûF_"a°ú~TtSpgiq<:MLìÈ\^°ú~>OvRÝ×D!fìÈ0Ë«N9_0¤30R3/0'2.745WN

enh4Ð>þÎDIOFµDM<^!pÝ×DI"%Þ!BRSV SpgiqìÈR<giqS¬R\_Mz8{S¿øT!í«:MZ0'1Ë«R"a°ú~SÝ×>X]`

S°ú8{S­ÝOfenh4ÐSSæSPJ

_>*0#
/1#
/2+
!0.265uÝRÝ×DI^TX]=!WITYGR\_OÑVM:_"¶!

]`Q:"I¥NZr!sS BRSV Rû

BRSV íÚSV²ïR$SpgiqìÈ

F_"a°ú~TpgiqìÈ«2'0345N

cÉAM:Ir!sNT!/¤0/0S CD6,

äwDM<^!0¤/60S·¹ÀR3/0'2.74

T ¸Hå<\U MHCclassII+CD/2,¸H å >5OOvQÝ×>X]`IBO=]!Äðí-0RpgiqìÈc²KItO9DM³

R\_Ý×O±;]`I"

ÿcÃF­R9^!0¤/60S°ú~>t

Antonis ]*/#
0+T!pgiqWITmq\^OvR³ÿN9KIBO=]!r!sN»Ûy(PBS)SìÈ«R BRSV cÆ¦

T BRSV SíRûDMã÷=L[Q¸HíCGIR<:M!pgiqìÈT PBS

ç<\UyçMz>P.C`M:IO±;]`ìÈ\^ CD2,T ¸Hå<\U CD6,T ¸I"Hå>ôRõF_BO!í«/.0N"aWC/,T ¸ H(γδT ¸ H)T Ù } !ë à°ú~SüCQÝ×>X]`_BOcFµDM

<\U:@QPmqj òáuSòáR¯:_"¶!/¤0/0R·¹DIr!s!tR@D?DM<^!ÜcÉAIÝ:SÔ[Ê<:M!KØ£"ScXåS¨Õ!CD2 T

BcöFQPÓSMzRÍRQNcID¸H[ CD6,T ¸HQPSÈ T ¸Hå!CD

M:_*/6+"Thomas ]*/3+T!BRSV 

0/,¸H(èÏ8¸H)å<\U MHCclassII+

íÚc7ÚDIS¼3JªOóN®»

CD/2 ¸H(ç}ý)åSõ>%D

!CD2,T ¸ H!CD6,T ¸ H < \ U WC

M1Y]`IBOT Antonius ]SÆ¦¢O/,T ¸HSõcºDM:_" tNTr!

x!DM:I"tNT0¤30S BRSV S

s\^cXå>OvR¨ÕDM<^!WC"a°ú~>ëpgiqìÈNTB]Q:o/,T ¸Hå>OvQ³ÿcÃDIBO=]!

,

,

&/3&

Journal of Japanese Society for Clinical Infections Disease
in Farm Animals Vol.4 No.1 2009

.*,/&7 RS )(-+<@5?;'E01Bi

M BRSV L|¼KRUß®Ó~µL

Stockhofe, N., Hensen, E. J., Lanqedijk,

ªçQÑÞL²¥çWRT=¤>G7

J. P. and Van der Most, R. G. 2003.

E?I;8SVE"

Vaccineinduced immunopathology during

Ellis S(1)!Patel S(--)M!BRSV ¢bovinerespiratorysyncytialvirus

|¼K97GdZ^e»£ Iá»£ WÕ

infection: exploring the parameters of

yA!dZ^e»£ Lñ{éÆpQ¯±pathogenesis. J. Virol. 77 : 1206712073.

WÚAG7U"M7CVPÅrdZ^/$Babcock, A., Jones, R. and Langemeier,e»£½L0*3fîK-x1£¹dZ

M. 2006. Examining death loss in Kansas^e»£W¤>G7E;!g!h LÔ¯Éµfeedlots.

;êKdZ^e»£AEi IÕyAGä

Report of Prog. 959. pp. 4652, Kanzas

kKªJ=!RS |¼¯êj½LÅrdZ^State Univ., Manhattan.

e»£; BRSV L¡¾|¼K9>UÔ¯Wä

Beef

CattleResearch2006,

0$Duff, G. C. and Galyean, M. L. 2007.

kKè¶AEI´@VE"NE!-3fîN

BOARD  INVITEDHÅrLdZ^e»£W¤>G7J:FEH

advances

M40+;Ô¯AE;!¨ËJ¯±W AEPL

stressed, newly received feedlot cattle.

MJ=!.'0xLëHãAE?I:Sd

J. Anim. Sci. 85 : 823840.

in

REVIEW :management

RecentofhighlyZ^e»£KRU¯±u;6FEI8

1$Ellis, J., West, K., Konoby, C., Leard, T.,

SVE"NE!-4fîj°HÔ¯AEM7

Gallo, G., Conlon, J. and Fitzgerald, N.

J:FE;!BRSV L¡¾|¼KRFGâo

2001.

;H<G7EsÒ·;8SVE"

respiratory syncytial virus vaccine inj°L¸º:S!ÊÐ½L1£¹dZ^

Efficacyofaninactivatedcalves. J. Am. Vet. Med. Assoc. 218 :e-x»£HMÊÐLDVSYXb]LÁ19731980.

q;:JTÆpAG9T BRSV |¼¯Wz¿

2$Fulton, R. W., Cook, B. J., Step, D. L.,KæÜBU?IMÌA7?I!ÊÐKÂBUConfer, A. W., Saliki, J. T., Payton, M. E.,1£dZ^eLÅr»£MÁqL°¬I

Burge, L. J., Welsh, R. D. and Blood, K.

Û·âoWOU?IH BRSV |¼¯Læ

S. 2002. Evaluation of health status ofÜKÂAGäH6U?I; @VE"

calvesandtheimpacton

feedlot

performance: Assessment of a retained!#&%$"

ownership-$Antonis, A. F., Claassen, E. A., Hensen, E.

calves. Can. J. Vet. Res. 66 : 173180.

programfor

postweaningJ., De Groot, R. J., De GrootMijnes, J.

3$Èlà}#Ön #ÙÇmï#­Ç×

D., Schrijver, R. S. and Van der Most, R.

Í#vÀð©$-55,$ÏçK¦ÃÔ¹

G. 2006. Kinetics of antiviral CD8 T cell

AE RS YXb]|¼¯$Î§w 0/%

responses during primary and post

050*054$

vaccination secondary bovine respiratory

4$Ø³m$.,,4$L|¼¯æÜdZ^syncytial virus infection. Vaccine 24 :e_c[a`$ÎÝtÄí«|¼¯w

15511561.

 /%35*40$.$Antonis, A. F., Schrijver, R. S., Daus, F.,

CD2AF=5?>863:$4"9 #!!%

5$òìå$.,,.$Y\ RS YXb]|¼¯$& -2 &

Immune response of vaccine and BRSV infection

Wd NmUV7E[523H6nR%Z

Immunopathol. 95 : 123133.

PGJ!QDXTCO&!9#;8#:<!
),.'),0"
iAa!pp")-"Thomas, L. H., Cook, R. S., Howard, C.
J., Gaddum, R. M. and Taylor, G. 1996.

)("QS \!QlM Y!Lb=k"*((+"

Influenceof

selectiveTlymphocyte

T Kh6f@4Fc"_e6j?B!]*

depletion on thed!g>`Pd!^I!pp"1)')(+"

gnotobiotic calves and the distribution))"Patel, J. R. and Didlick, S. A. 2004.

of different T-lymphocyte subsets followingofchallenge

vaccinesyncytial virus. Res. Vet. Sci. 61 : 38·44.

bovinerespiratory

bovinepathology

Evaluation of efficacy of an inactivatedagainst

with

lung

respiratorysyncytial virus in calves with maternal)."Verhoeff, J., Van der Ban, M. and Van

antibodies. Am. J. Vet. Res. 65 : 417Nieuwstadt, A. P. 1984. Bovine respiratory421.

syncytial virus infections in young dairy)*"Peters, A. R., Thevasagayam, S. J.,
Wiseman, A. and Salt, J.

S.

cattle: Clinical and haematological findings.
Vet. Rec. 114 : 912.

2004.

)/"Werling, D., Collins, R. A., Taylor, G. andDuration of immunity of a quadrivalentdiseases

Howard, C. J. 2002. Cytokine responses

caused by BHV1, PI3V, BVDV, andof bovine dendritic cells and T cells

BRSV in experimentally infected calves.

following exposure to live or inactivatedPrev. Vet. Med. 66 : 6377.

bovine respiratory syncytial virus. J.

vaccineagainstrespiratry)+"Platt, R., Burdett, W. and Roth, J. A.

Leukoc. Biol. 72 : 297304.

2006. Induction of antigenspecific Tcell)0"Woolms, A. R., Loneragan, G. H., Hawkins,subset activation to bovine respiratory

L. L. and Williams, S. M. 2005. Baseline

disease viruses by a modifiedlive virus

management

vaccine. Am. J. Vet. Res. 67 : 11791184.

health data reported by US feedlots),"Sandbulte, M. R. and Roth, J. A. 2003.

responding to a survey regarding acutePriming of multiple T cell subsets byinterstitial pneumonia. Bovine Pract. 39 :modifiedlive and inactivated respiratory116124.

Practicesandanimalsyncytial virus vaccines. Vet. Immunol.

$)/$

Journal of Japanese Society for Clinical Infections Disease
in Farm Animals Vol.4 No.1 2009

.*,/&7 RS )(-+<@5?;'E01B

Protective efficacy and immune responses to natural infectionof bovine respiratory syncytial virus (BRSV) in beef cattlewith additional inoculation of five!way modified live vaccine
Daisaku Watanabe1), Momoko Taguchi1), Takaaki Ando2),
Hiromichi Ohtsuka1), Hidetomo Sasaki3),
Masaomi Nakasato3), Masaaki Oikawa1)
1) School of Veterinary Medicine,Kitasato University
2) School of Veterinary Medicine,Rakuno Gakuen University
3) Towada livestock Hygiene Service Center

ABSTRACT
We had been investigating the immune response to a five$way mixed modified live
vaccines, which contains bovine respiratory syncytial virus (BRSV). During thisinvestigation a natural infection of BRSV occurred at a beef farm, which raises 130
Japanese Black cattle. From January 21 to February 10, 2008, 38 out of 68 investigatedcattle (10$17 months of age) showed fever, cough and anorexia with marked increase in
antibody titer to BRSV. All investigated cattle received the first vaccination with 5$way
mixed modified live virus at 4 to 7 months of age. In order to examine the effect of thetiming of additional vaccination on protection of BRSV infection, these cattle were divided
into three groups according to the date of vaccination; Groups I and II received
vaccination prior to the outbreak of BRSV infection, either on November 23 or December
22, 2007, respectively, and Group III was vaccinated on January 21, 2008, during theoutbreak. Significantly lower incidence of treatment and higher serum neutralization
antibody titers in the post vaccination serum (February 18, 2008) were observed inGroups I and II compared with Group III. In all groups, the number of granulocytes
decreased, and the number of CD3+CD45R+T (naive T) cells, CD4+T (helper T) cells, CD8+
T (cytotoxic T) cells, CD21+ (mature B) cells and MHC classII+CD14+ cells (activatedmonocytes) increased significantly on January 21, 2008. These results suggest thatchanges of immunocytes were caused by BRSV infection. An additional inoculation of 5$
way mixed modified live vaccines might be useful for prevention of BRSV infection.
"Key Word: antibody titer, BRSV, cattle, immunocyte, vaccination#

CD2AF=5?>863:$4"9 #!!%! %& !